HC Wainwright Analysts Decrease Earnings Estimates for NTLA

Key Points

• HC Wainwright lowered its FY2026 EPS estimate for Intellia Therapeutics to a loss of $3.24 per share from $3.06, while maintaining a Buy rating and a $25 price target.
• Intellia’s latest quarter missed expectations: it reported a loss of $0.91 per share versus the $0.80 consensus, and revenue of $7.16 million versus $9.74 million expected; revenue fell 47.8% year over year.
• Analyst views are mixed: the stock has an average Hold rating and a consensus price target of $21.44. Shares opened at $12.11 in the article’s report.

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Analysts at HC Wainwright cut their FY2026 earnings per share (EPS) estimates for Intellia Therapeutics in a research note issued on Friday, November 6th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($3.24) per share for the year, down from their prior forecast of ($3.06). HC Wainwright currently has a "Buy" rating and a $25.00 price target on the stock. The consensus estimate for Intellia Therapeutics' current full-year earnings is ($3.21) per share. HC Wainwright also issued estimates for Intellia Therapeutics' Q1 2027 earnings at ($0.82) EPS, Q3 2027 earnings at ($0.82) EPS, Q4 2027 earnings at ($0.78) EPS and FY2027 earnings at ($3.17) EPS.

Other analysts have also recently issued reports about the company. Citigroup reaffirmed a "market outperform" rating on shares of Intellia Therapeutics in a research note on Tuesday, August 25th. Wedbush lifted their price objective on shares of Intellia Therapeutics from $12.00 to $13.00 and gave the stock a "neutral" rating in a research note on Wednesday, September 9th. Evercore raised shares of Intellia Therapeutics from a "hold" rating to an "outperform" rating and set a $24.00 price objective on the stock in a research note on Friday, August 7th. Wolfe Research cut shares of Intellia Therapeutics from a "peer perform" rating to an "underperform" rating and set a $9.00 price objective for the company. in a report on Wednesday, July 15th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Intellia Therapeutics in a research note on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, seven have given a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $21.44.

Intellia Therapeutics Stock Performance

Shares of NTLA opened at $12.11 on Tuesday. Intellia Therapeutics has a 1 year low of $7.95 and a 1 year high of $18.48. The stock's 50-day moving average price is $12.08 and its two-hundred day moving average price is $13.04.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.11). Intellia Therapeutics had a negative net margin of 672.16% and a negative return on equity of 57.79%. The company had revenue of $7.16 million during the quarter, compared to analyst estimates of $9.74 million. During the same period in the previous year, the company posted ($0.92) EPS. The company's quarterly revenue was down 47.8% compared to the same quarter last year.

Insiders Place Their Bets

In other Intellia Therapeutics news, CEO John M. Leonard sold 9,000 shares of Intellia Therapeutics stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $11.99, for a total transaction of $107,910.00. Following the transaction, the chief executive officer directly owned 1,138,064 shares in the company, valued at approximately $13,645,387.36. The trade was a 0.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 3.50% of the company's stock.

Institutional Investors Weigh In On Intellia Therapeutics

Hedge funds have recently modified their holdings of the business. Bank of America Corp DE raised its stake in shares of Intellia Therapeutics by 11.2% in the 1st quarter. Bank of America Corp DE now owns 1,381,703 shares of the company's stock valued at $17,713,000 after purchasing an additional 139,325 shares during the period. Royal Bank of Canada lifted its holdings in shares of Intellia Therapeutics by 1,082.1% in the first quarter. Royal Bank of Canada now owns 465,499 shares of the company's stock valued at $5,968,000 after purchasing an additional 426,121 shares in the last quarter. Headlands Technologies LLC acquired a new position in shares of Intellia Therapeutics during the second quarter worth about $1,595,000. Assenagon Asset Management S.A. acquired a new position in shares of Intellia Therapeutics during the third quarter worth about $3,875,000. Finally, BlackRock Inc. bought a new position in shares of Intellia Therapeutics during the second quarter worth about $260,721,000. Institutional investors and hedge funds own 88.77% of the company's stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genome-editing treatments for serious diseases. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company uses CRISPR/Cas9 technology to make targeted changes to DNA.

Its research includes in vivo therapies, which are designed to edit genes inside a patient's body, and ex vivo approaches, which involve modifying cells outside the body before they are returned to the patient. Intellia's investigational programs have included treatments for transthyretin amyloidosis and hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.